Trending NewsTrending NewsNASDAQ:ETON Eton Pharmaceuticals (ETON) Stock Price, News & Analysis $56.46 +9.31 (+19.75%) Closing price 04:00 PM EasternExtended Trading$57.03 +0.57 (+1.01%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Eton Pharmaceuticals Stock (NASDAQ:ETON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eton Pharmaceuticals alerts:Sign Up Key Stats Today's Range$51.82▼$58.5950-Day Range$47.15▼$61.9652-Week Range$14.27▼$66.37Volume1.27 million shsAverage Volume435,252 shsMarket Capitalization$1.61 billionP/E Ratio37.39Dividend YieldN/APrice Target$77.00Consensus RatingBuy Company Overview Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications. Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate. The company has also marketed hospital products such as Biorphen, an injectable phenylephrine product, and Rezipres, an injectable ephedrine sulfate product. Its portfolio may include products developed internally as well as products acquired or licensed from other pharmaceutical companies. Founded in 2017, Eton is based in the United States and primarily serves the U.S. pharmaceutical market. The company works with external partners for aspects of product development, manufacturing and commercialization, while concentrating its own resources on identifying, obtaining regulatory approval for and commercializing specialized medicines. Eton Pharmaceuticals is led by Chief Executive Officer Sean Brynjelsen, who co-founded the company.AI Generated. May Contain Errors. Read More Eton Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreETON MarketRank™: 4.138093317195 of 5 starsEton Pharmaceuticals scored higher than 83% of companies evaluated by MarketBeat, and ranked 67th out of 886 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingEton Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialEton Pharmaceuticals has a consensus price target of $77.00, representing about 36.4% upside from its current price of $56.46.Amount of Analyst CoverageEton Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Eton Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth71.68% Earnings GrowthEarnings for Eton Pharmaceuticals are expected to grow by 71.68% in the coming year, from $1.13 to $1.94 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eton Pharmaceuticals is 148.58, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.49.Price to Earnings Ratio vs. SectorThe P/E ratio of Eton Pharmaceuticals is 148.58, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.03.Price to Book Value per Share RatioEton Pharmaceuticals has a P/B Ratio of 57.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.14% of the float of Eton Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEton Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eton Pharmaceuticals has recently increased by 5.96%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEton Pharmaceuticals does not currently pay a dividend.Dividend GrowthEton Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.40 News SentimentEton Pharmaceuticals has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Eton Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 13 people have searched for ETON on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat Follows7 people have added Eton Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Eton Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,809,672.00 in company stock.Percentage Held by Insiders16.49% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions27.86% of the stock of Eton Pharmaceuticals is held by institutions.Read more about Eton Pharmaceuticals' insider trading history. Receive ETON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ETON Stock News HeadlinesEton Pharmaceuticals Stock Gains as 3Q Revenue More Than DoublesNovember 6 at 11:33 AM | marketwatch.comEton Pharma jumps after Q3 beat and guidance hikeNovember 6 at 11:33 AM | msn.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 6 at 1:00 AM | Behind the Markets (Ad)Eton Pharma (ETON) Q3 2026 Earnings Call TranscriptNovember 6 at 6:27 AM | finance.yahoo.comEton Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 6 at 1:26 AM | marketscreener.comMEton Pharmaceuticals, Inc. (ETON) Q3 2026 Earnings Call TranscriptNovember 5 at 10:00 PM | seekingalpha.comEton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal TolerabilityNovember 5 at 8:25 PM | markets.businessinsider.comEton Pharmaceuticals (NASDAQ:ETON) Insider David Krempa Sells 4,166 Shares of Company StockOctober 7, 2026 | insidertrades.comSee More Headlines ETON Stock Analysis - Frequently Asked Questions How have ETON shares performed this year? Eton Pharmaceuticals' stock was trading at $16.91 on January 1st, 2026. Since then, ETON shares have increased by 233.9% and is now trading at $56.46. How were Eton Pharmaceuticals' earnings last quarter? Eton Pharmaceuticals, Inc. (NASDAQ:ETON) issued its quarterly earnings data on Thursday, November, 5th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.19. The company had revenue of $57.93 million for the quarter, compared to analysts' expectations of $41.99 million. Eton Pharmaceuticals had a net margin of 12.02% and a trailing twelve-month return on equity of 40.13%. Read the conference call transcript. When did Eton Pharmaceuticals IPO? Eton Pharmaceuticals (ETON) raised $22 million in an initial public offering (IPO) on Wednesday, November 14th 2018. The company issued 3,600,000 shares at $6.00 per share. National Securities Corporation acted as the underwriter for the IPO. Who are Eton Pharmaceuticals' major shareholders? Eton Pharmaceuticals' top institutional shareholders include Westside Investment Management Inc. (1.40%), Bridge City Capital LLC (0.30%), Robeco Institutional Asset Management B.V. (0.16%) and Russell Investments Group Ltd. (0.11%). Insiders that own company stock include Opaleye Management Inc, James R Gruber, Paul V Maier, Jennifer Mckie Adams and David Krempa. View institutional ownership trends. How do I buy shares of Eton Pharmaceuticals? Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eton Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eton Pharmaceuticals investors own include NVIDIA (NVDA), Micron Technology (MU), Palantir Technologies (PLTR), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings11/05/2026Today11/06/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ETON's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ETON CIK1710340 Webwww.etonpharma.com Phone(847) 787-7361FaxN/AEmployees44Year Founded2017Price Target and Rating Average Price Target for Eton Pharmaceuticals$77.00 High Price Target$80.00 Low Price Target$70.00 Potential Upside/Downside+36.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.38 Trailing P/E Ratio148.58 Forward P/E Ratio29.10 P/E GrowthN/ANet Income-$4.60 million Net Margins12.02% Pretax Margin12.07% Return on Equity40.13% Return on Assets12.37% Debt Debt-to-Equity Ratio0.41 Current Ratio1.52 Quick Ratio1.30 Sales & Book Value Annual Sales$79.95 million Price / Sales20.18 Cash Flow$0.01 per share Price / Cash Flow9,785.46 Book Value$0.98 per share Price / Book57.61Miscellaneous Outstanding Shares28,580,000Free Float23,870,000Market Cap$1.61 billion OptionableOptionable Beta0.89 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:ETON) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public co...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | SponsoredYour first step can stay on paperIncome Blueprint, created by Matt, helps traders find and evaluate options opportunities. In his walkthrough, ...StocksToTrade | SponsoredThis 10.3% income window closed once. It's open again.Todd Phillips has spent 30 years studying safe-money income. His test for real retirement income: can it promi...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
